作为糖尿病和阿尔茨海默病之间的潜在联系GLP-1R
Shujun Li1, Nanqu Huang2,3, Mei Wang2,3
1Key Laboratory of Basic Pharmacology and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Frontiers in aging neuroscience
|August 8, 2025
概括
葡萄糖类-1受体 (GLP-1R) 是阿尔茨海默病 (AD) 和糖尿病 (DM) 之间的关键联系. 针对GLP-1R可能为这两种情况提供双重治疗效益.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 和糖尿病 (DM) 具有共同的病理生理机制,特别是大脑中断的胰岛素信号传递.
- 葡萄糖类-1受体 (GLP-1R) 在DM中的血糖控制中起着至关重要的作用,并在AD中表现出神经保护作用.
研究的目的:
- 探索GLP-1R作为潜在的治疗点的作用,将AD和DM联系起来.
- 审查GLP-1R影响AD和DM病理的机制.
主要方法:
- 文献综述和现有关于GLP-1R在AD和DM中的研究的综合.
- 对两种疾病中GLP-1R作用背后的分子机制的分析.
主要成果:
- GLP-1R通过增强胰岛素分泌和信号传递来调节DM中的血糖控制.
- GLP-1R通过抗炎作用,减少粉样β (Aβ) 沉积,增强Aβ清除和改善胰岛素信号,减轻AD病理.
- 大脑中的共享破坏的胰岛素信号通路突出显示了GLP-1R在两种疾病中的关键作用.
结论:
- GLP-1R是DM和AD的重要治疗点,可能成为这些疾病之间的桥梁.
- 对GLP-1R分子机制的进一步研究是有必要的.
- 开发GLP-1R激动剂可能会导致针对同时出现AD和DM的患者的综合治疗策略.
相关概念视频
Glucagon-like Receptor Agonists
418
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
418
Psychoneuroimmunology: Diabetes and Cancer
62
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
62
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
G Protein-coupled Receptors
13.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.4K
Dipeptidyl Peptidase 4 Inhibitors
257
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
257
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261


